ZA200606203B - Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof - Google Patents

Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Info

Publication number: ZA200606203B
Authority: ZA; South Africa
Prior art keywords: metabolic; treatment; methods; related disorders; tetrazole derivatives
Prior art date: 2003-10-31

Application number

ZA200606203A

Other languages

English (en)

Inventor

Semple Graeme

Philip J Skinner

Gharbaqui Tawfik

Jung Jae-Kyi

Raghavan Subharekha

James R Tata

Schrader Thomas

Steven L Colletti

Jason E Imbriglio

Liang Rui

Schmidt Darby

Original Assignee

Arena Pharm Inc

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-31

Filing date

2006-07-26

Publication date

2007-04-25

2006-07-26 Application filed by Arena Pharm Inc, Merck & Co Inc filed Critical Arena Pharm Inc

2007-04-25 Publication of ZA200606203B publication Critical patent/ZA200606203B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200606203A 2003-10-31 2006-07-26 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof ZA200606203B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US51623803P	2003-10-31	2003-10-31

Publications (1)

Publication Number	Publication Date
ZA200606203B true ZA200606203B (en)	2007-04-25

Family

ID=34572875

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ZA200603419A ZA200603419B (en)	2003-10-31	2006-04-28	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ZA200606203A ZA200606203B (en)	2003-10-31	2006-07-26	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
ZA200603419A ZA200603419B (en)	2003-10-31	2006-04-28	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Country Status (37)

Country	Link
US (2)	US8637555B2 (xx)
EP (2)	EP1599469B1 (xx)
JP (2)	JP4533898B2 (xx)
KR (1)	KR100850591B1 (xx)
CN (1)	CN1867562B (xx)
AR (1)	AR046611A1 (xx)
AT (1)	ATE328880T1 (xx)
AU (1)	AU2004287861B2 (xx)
BR (1)	BRPI0415631A (xx)
CA (1)	CA2539985C (xx)
CO (1)	CO5690551A2 (xx)
CR (1)	CR8270A (xx)
CY (1)	CY1105479T1 (xx)
DE (1)	DE602004001134T2 (xx)
DK (1)	DK1599469T3 (xx)
EA (1)	EA011484B1 (xx)
EC (1)	ECSP066529A (xx)
ES (1)	ES2267077T3 (xx)
GE (1)	GEP20094801B (xx)
HR (1)	HRP20060286T3 (xx)
IL (1)	IL174042A0 (xx)
IS (1)	IS2372B (xx)
MA (1)	MA28171A1 (xx)
MX (1)	MXPA06004556A (xx)
MY (1)	MY140410A (xx)
NO (1)	NO20062509L (xx)
NZ (1)	NZ546285A (xx)
PE (1)	PE20050483A1 (xx)
PL (1)	PL1599469T3 (xx)
PT (1)	PT1599469E (xx)
RS (1)	RS20060290A (xx)
SI (1)	SI1599469T1 (xx)
TN (1)	TNSN06150A1 (xx)
TW (1)	TWI258478B (xx)
UA (1)	UA86783C2 (xx)
WO (1)	WO2005044816A1 (xx)
ZA (2)	ZA200603419B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7094572B2 (en)	2003-03-14	2006-08-22	Bristol-Myers Squibb	Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2005051937A2 (en) *	2003-11-21	2005-06-09	Arena Pharmaceuticals, Inc.	4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
US20070244107A1 (en) *	2004-08-25	2007-10-18	Waters M Gerard	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
EP1811996A1 (en) *	2004-11-05	2007-08-01	Arena Pharmaceuticals, Inc.	Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) *	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (en)	2005-04-28	2008-01-16	Merck Sharp & Dohme Limited	A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles
PE20070097A1 (es)	2005-06-28	2007-03-08	Merck Sharp & Dohme	Agonistas del receptor de niacina y composiciones que contienen tales compuestos
DE102006021733A1 (de) *	2006-05-09	2007-11-22	Bayer Healthcare Ag	3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de)	2006-09-15	2008-03-27	Bayer Healthcare Ag	Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de)	2008-12-19	2010-09-02	Lerner, Zinoviy, Dipl.-Ing.	Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2014011926A1 (en)	2012-07-11	2014-01-16	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2901636A1 (en)	2013-02-21	2014-08-28	Adverio Pharma Gmbh	Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
JP6453216B2 (ja) *	2013-07-23	2019-01-16	エーザイ・アール・アンド・ディー・マネジメント株式会社	ヘテロ縮合環化合物
CN103755637A (zh) *	2013-12-26	2014-04-30	平湖优康药物研发有限公司	一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
CA3096145A1 (en) *	2019-10-11	2021-04-11	Royal Bank Of Canada	System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH02178263A (ja) *	1988-12-27	1990-07-11	Kaken Pharmaceut Co Ltd	アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en)	1991-08-08	1992-07-28	Ortho Pharmaceutical Corporation	Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en)	1996-04-12	1999-09-07	Sumitomo Pharmaceuticals Company, Limited	Piperidinylpyrimidine derivatives
DE69739593D1 (de)	1996-12-23	2009-11-05	Bristol Myers Squibb Pharma Co	Stickstoffhaltige heterocyclen als faktor xa-hemmer
DE69941777D1 (de)	1998-03-10	2010-01-21	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
NZ521192A (en)	2000-03-09	2005-01-28	Ono Pharmaceutical Co	Indole derivatives, process for preparation of the same and use thereof
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
CA2413702A1 (en)	2000-06-28	2002-01-03	Teva Pharmaceuticals Industries Ltd.	Carvedilol
KR100815681B1 (ko)	2000-06-30	2008-03-20	글락소 그룹 리미티드	퀴나졸린 디토실레이트 염 화합물
US6410583B1 (en)	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de)	2000-11-22	2002-05-23	Bayer Ag	Neue Carbamat-substituierte Pyrazolopyridinderivate
DE60215000T2 (de)	2001-05-23	2007-08-09	Merck Frosst Canada & Co, Kirkland	Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
MXPA03010822A (es)	2001-06-01	2004-02-17	Hoffmann La Roche	Derivados de pirimidina, triazina y pirazina como receptores de glutamato.
WO2003002544A1 (en)	2001-06-26	2003-01-09	Bristol-Myers Squibb Company	N-heterocyclic inhibitors of tnf-alpha expression
JP3968076B2 (ja)	2001-06-27	2007-08-29	アールエステックコーポレイション	新しいキラルサレン化合物、キラルサレン触媒及びこれを利用したラセミックエポキシ化合物からキラル化合物を製造する方法
EP1424335A4 (en)	2001-09-07	2005-11-16	Ono Pharmaceutical Co	INDOLE DERIVATIVES
DE10148617A1 (de)	2001-09-25	2003-04-24	Schering Ag	Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es)	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
ATE516277T1 (de)	2002-03-19	2011-07-15	Ono Pharmaceutical Co	Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
DE10220570A1 (de)	2002-05-08	2003-11-20	Bayer Ag	Carbamat-substituierte Pyrazolopyridine
WO2004033431A2 (en)	2002-10-04	2004-04-22	Arena Pharmaceuticals, Inc.	Hydroxypyrazoles for use against metabolic-related disorders
CA2501134A1 (en) *	2002-10-10	2004-04-22	Arena Pharmaceuticals, Inc.	5-substituted 2h-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
DE10261131A1 (de)	2002-12-20	2004-07-01	Grünenthal GmbH	Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
US20070032537A1 (en)	2003-06-13	2007-02-08	Arena Pharmaceuticals, Inc.	5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases
GB0319126D0 (en)	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
GB0319124D0 (en)	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
TWI258478B (en) *	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
PT1781657E (pt)	2004-02-14	2013-05-23	Glaxosmithkline Ip Dev Ltd	Medicamentos com actividade no receptor hm74a
US20070244107A1 (en)	2004-08-25	2007-10-18	Waters M Gerard	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
EP1811996A1 (en)	2004-11-05	2007-08-01	Arena Pharmaceuticals, Inc.	Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (en)	2005-04-28	2008-01-16	Merck Sharp & Dohme Limited	A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles

2004
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de not_active Expired - Lifetime
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/en not_active Ceased
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es not_active Expired - Lifetime
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active Expired - Fee Related
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
- 2004-10-29 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
- 2004-10-29 CA CA2539985A patent/CA2539985C/en not_active Expired - Fee Related
- 2004-10-29 EP EP04818324A patent/EP1599469B1/en not_active Expired - Lifetime
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 EP EP06005248A patent/EP1683794A1/en not_active Withdrawn
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending

Also Published As

Publication number	Publication date
DK1599469T3 (da)	2006-10-09
NO20062509L (no)	2006-06-26
MXPA06004556A (es)	2006-07-06
CA2539985C (en)	2010-02-16
JP2010163448A (ja)	2010-07-29
EP1599469B1 (en)	2006-06-07
CO5690551A2 (es)	2006-10-31
WO2005044816A1 (en)	2005-05-19
US20070072924A1 (en)	2007-03-29
NZ546285A (en)	2010-04-30
TWI258478B (en)	2006-07-21
PT1599469E (pt)	2006-10-31
US8637555B2 (en)	2014-01-28
TNSN06150A1 (en)	2007-11-15
CN1867562B (zh)	2011-07-13
JP2007509181A (ja)	2007-04-12
EA200600879A1 (ru)	2006-10-27
AU2004287861A1 (en)	2005-05-19
EP1599469A1 (en)	2005-11-30
SI1599469T1 (sl)	2006-10-31
CN1867562A (zh)	2006-11-22
BRPI0415631A (pt)	2006-12-12
CY1105479T1 (el)	2010-07-28
ATE328880T1 (de)	2006-06-15
RS20060290A (sr)	2008-11-28
UA86783C2 (ru)	2009-05-25
GEP20094801B (en)	2009-10-26
HK1076468A1 (en)	2006-01-20
HRP20060286T3 (en)	2007-03-31
EA011484B1 (ru)	2009-04-28
TW200530221A (en)	2005-09-16
JP4533898B2 (ja)	2010-09-01
CA2539985A1 (en)	2005-05-19
KR100850591B1 (ko)	2008-08-05
ZA200603419B (en)	2006-10-25
PL1599469T3 (pl)	2006-10-31
AR046611A1 (es)	2005-12-14
ECSP066529A (es)	2006-10-10
MA28171A1 (fr)	2006-09-01
KR20060073974A (ko)	2006-06-29
PE20050483A1 (es)	2005-08-25
AU2004287861B2 (en)	2008-08-14
US20060217562A1 (en)	2006-09-28
MY140410A (en)	2009-12-31
EP1683794A1 (en)	2006-07-26
IS2372B (is)	2008-06-15
IS8481A (is)	2006-05-24
DE602004001134D1 (de)	2006-07-20
CR8270A (es)	2006-10-06
IL174042A0 (en)	2006-08-01
DE602004001134T2 (de)	2007-04-19
ES2267077T3 (es)	2007-03-01

Publication	Publication Date	Title
IL183654A0 (en)	2007-09-20	Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related disorders
SI1599467T1 (sl)	2010-09-30	Novi cianopiridinski derivati uporabni pri zdravljenju raka in drugih motenj
PT1644021E (pt)	2013-01-30	Métodos e composições para o tratamento de distúrbios gastrointestinais
IL174918A0 (en)	2008-04-13	Methods and reagents for the treatment of immunoinflammatory disorders
IL172194A0 (en)	2011-08-01	Methods and compositions for treating amyloid-related diseases
IL174185A0 (en)	2006-08-01	Methods and reagents for the treatment of immunoinflammatory disorders
AU2003223207A8 (en)	2003-09-16	Scds as modifiers of the p53 pathway and methods of use
PL378294A1 (pl)	2006-03-20	Pochodne izochinolinowe i sposoby ich stosowania
EP1699431A4 (en)	2012-09-19	COMPOSITIONS FOR THE TREATMENT OF EARLIER DISEASES AND APPLICATION PROCEDURES
AU2003291342A1 (en)	2004-06-07	Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
IL174042A0 (en)	2006-08-01	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
AU2003286741A8 (en)	2004-11-26	Methods and compositions for diagnosis and therapy of parkin-associated disorders
IL182436A0 (en)	2007-07-24	Thienopyridinone compounds and methods of treatment
ZA200410409B (en)	2006-05-31	Use of thio-oxindole derivatives in treatment of hormonerelated conditions
IL178996A0 (en)	2007-03-08	Thienopyridinone compounds and methods of treatment
AU2003287909A8 (en)	2004-08-10	Electro-therapeutic device and method of electro-therapeutic treatment
ZA200410157B (en)	2006-05-31	Methods of treating gastrointestinal and genitorinary pain disorders using vanilafaxin and derivatives
ZA200510170B (en)	2006-11-29	Method of reducing the harmful effects of orally or transdermally delivered nicotine
GB0308382D0 (en)	2003-05-21	Therapeutic methods and means
GB0324523D0 (en)	2003-11-26	Compositions and methods of treatment
IL166062A0 (en)	2006-01-15	Compositions and methods for therapeutic treatment
EP1684795A4 (en)	2009-07-29	METHODS AND AGENTS FOR THE TREATMENT OF CANCER
GB0221712D0 (en)	2002-10-30	Methods of treatment
GB0327975D0 (en)	2004-01-07	Methods of treatment
IL176041A0 (en)	2006-10-05	Compositions for treatment of ear disorders and methods of use thereof